Citi lowered the firm’s price target on Qiagen (QGEN) to $38 from $55 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen price target lowered to $38 from $44 at Barclays
- Qiagen upgraded to Outperform from Neutral at Baird
- Qiagen Sets Date for Publication of 2025 Annual Financial Report
- Qiagen Kept at Hold as Guidance Cut and QuantiFERON Weakness Offset H2 Rebound Hopes and Heighten Execution Risk
- Closing Bell Movers: Sanmina jumps over 10% on earnings beat